Novel therapeutic approaches with conventional chemotherapy and monoclonal antibody combinations have improved the complete remission rates in chronic lymphocytic leukemia. However, cure remains elusive, particularly in fludarabine-refractory patients, whose prognosis remains poor. Autologous stem cell transplantation (SCT) has been explored for such patients, lengthening the time to treatment failure in selected patients, but there is little hope that it will improve the cure rate. The strategy is particularly ineffective in patients with poor biological prognostic factors, such as abnormal cytogenetics and unmutated immunoglobulin heavy-chain variable region. Allogeneic SCT remains the only curative approach, producing an extended disease-free survival in 25-60%, mainly via the graft-versus-leukemia effect. The treatment-related mortality with such an approach has been significant, however, with a 30-40% risk of death within 100 days of the transplant. Nonmyeloablative (NMA) conditioning regimens may produce high response rates and lower morbidity, especially for patients with chemosensitive disease. Randomized trials designed according to the new biologic prognostic parameters described in chronic lymphocytic leukemia are required to better define the role of NMA SCT in the near future.
Chronic lymphocytic leukemia (CLL), the most frequent form of leukemia in Western countries, accounts for approximately 25% of leukemias. It predominates in elderly patients: the median age at diagnosis is 65 years. 1, 2 The disease remains incurable with standard treatments. 3, 4 Autologous and allogeneic blood and marrow transplants, first extensively evaluated for the treatment of lymphomas and myeloid leukemias, 5, 6 have decreased morbidity and mortality as a result of improvements in stem cell procedures and supportive care ( Table 1) . As a result, there has been an increase in the use of stem cell transplantation (SCT) in CLL. 7 Over the last few years, more data have become available to indicate that allogeneic transplantation is an effective, potentially curative approach for CLL, 8, 9 based on a potent graft-versus-leukemia (GVL) effect. 10, 11 Treatment with high-dose myeloablative chemoradiotherapy (HDCT) has, however, been associated with a substantial treatment-related mortality (TRM). Preliminary data involving less toxic, NMA preparative regimens have demonstrated a significant reduction of mortality, while still producing durable clinical and molecular remissions after allogeneic transplantation. 12 Consideration of the role and timing of transplantation-based therapies requires analysis of treatment alternatives. In addition, important prognostic factors have been recently identified in patients with CLL, making it 'one diagnosis for different diseases'. [13] [14] [15] This review outlines the role of autologous and allogeneic SCT in this era of evolving understanding of the biology of CLL.
Treatment alternatives for CLL
Complementary mechanisms of action and nonoverlapping toxicity have been the basis for combining agents in new chemotherapeutic regimens for CLL. Laboratory analysis revealed that fludarabine inhibits repair of alkylatorinduced interstrand DNA crosslinks. 16 In vitro, fludarabine downmodulates complement-resistance proteins CD55 and CD59, thereby potentially making cells more sensitive to monoclonal antibody-dependent complement-mediated cytotoxicity. 17 A recent Cancer and Leukemia Group B randomized trial has demonstrated improved complete remission (CR) rates with concurrent administration of fludarabine with rituximab compared to sequential administration in previously untreated patients. 18 The Keating et al regimen of fludarabine, cyclophosphamide and rituximab regimen consisted of six cycles of treatment given monthly; rituximab was given on day 1 at 375 mg/m 2 in the first cycle and then at 500 mg/m 2 in subsequent cycles. Fludarabine 25 mg/m 2 /day and cyclophosphamide 250 mg/m 2 /day were both given for 3 days in each cycle. 19 To date, 202 previously untreated patients with CLL have received this regimen. In all, 68% of patients achieved CR. Impressively, half of patients who achieved a CR using NCI Working Group criteria had no evidence of clonal cells by polymerase chain reaction (PCR)-based methodology. 19 The potential impact of these remission rates upon survival remains unknown, however. The prognosis remains particularly poor in relapsing patients and in patients who are refractory to fludarabine-based regimens. The median survival of the latter group is less than a year. 4 Salvage therapy, using Campath-IH, an anti-CD52 monoclonal antibody, in this setting, resulted in a 33% response rate, but most patients relapsed within 1 year without demonstrating a clear survival benefit. 20 Treatment with high-dose chemotherapy CLL cells are very sensitive to alkylating agents and radiation, the cornerstones of high-dose preparative regimens, and exhibit a steep dose-response effect. These characteristics make them attractive targets for high-dose chemotherapy and SCT. Total body irradiation (TBI) is most commonly used for conditioning, but some studies involved busulfan/cyclophosphamide combinations or carmustine-based regimens, particularly in patients with contraindications to radiation.
Autologous SCT
Use of autologous SCT in CLL is limited by the involvement of the blood and bone marrow as part of the natural history of the disease. Fludarabine-based regimens have produced marrow remissions, offering the opportunity to collect marrow grafts with eradicated or minimal disease. 19 High-dose chemotherapy with purged marrow or blood SCT has been studied as cytoreductive treatment for CLL. [21] [22] [23] [24] [25] [26] The studies have suffered from heterogeneity in the eligibility criteria, in definitions of high-risk or poor prognosis, in purging strategies, in supportive care and in response criteria. Therefore, it is hard to evaluate the results (Table 2) .
Studies from the MD Anderson and the University of Nebraska reported transient remissions in heavily pretreated patients. 22, 23 Those studies reported a relapse rate of 56 and 63% with a median follow-up of 18 and 23.5 months, respectively. More encouraging results were reported from the Dana Farber Cancer Center, 21 where investigators focused on patients early in the course of their disease, with a low tumor burden. In those studies, the authors reported 4-year estimated disease-free survival (DFS) of 63%, and the estimated overall survival (OS) was 85%.
Larger studies from the European Group for Blood and Marrow Transplantation (EBMT) 24 and from The International Project for CLL/Transplants have also reported a 4-year OS of 87 and 65%, respectively. 25, 27 It should be noted that 45% of patients in the EBMT group were in CR at the time of transplantation.
Although extended CR was achieved in approximately 80% of patients after high-dose chemoradiotherapy and autologous SCT, it is not clear that cure is possible with this strategy. This is especially so for patients who have had multiple relapses. It should be noted that such patients had chemosensitive disease and near-remission marrow at the Increasing the size of donor pool through cord blood and mismatched transplants Stem cell transplantation for CLL E Jabbour et al time of stem cell collection. They had, however, bulky lymphadenopathy, which was the first site of relapse in these patients after autologous SCT. 22 This suggests that chemosensitivity alone is insufficient to predict success.
Contributory factors for the failure of autologous SCT. In the last two decades, peripheral blood has become the main source for hematopoietic stem cells. Fludarabine, however, may affect the ability to mobilize stem cells, especially in heavily pretreated patients. Michallet et al 28 reported that a delay of more than 2 months between the last course of fludarabine and stem cell mobilization was strongly associated with a better stem cell collection.
Relapse remains the most common cause of failure after autologous SCT. Gene marking studies have demonstrated that malignant cells contaminating the autologous graft in patients with myeloid leukemia can contribute to relapse. 29, 30 In order to diminish the potential risk of relapse due to the reinfusion of malignant cells, several investigators have depleted B-lymphoid lineage cells from the harvest by targeting cell surface markers including CD19 or CD20 shared by normal as well as malignant B cells with magnetic monoclonal antibody in vitro or by positive selection of stem cells by excluding malignant cells from the autograft. 31, 32 This has led to a significant degree of B-cell depletion of the harvest. 33 With the exception of one series, no other study could demonstrate an improved outcome with purging of CLL autografts prior to transplantation. Paradoxically, even when tumor-containing stem cells are infused during the autotransplant, molecular remissions are often obtained. 32 Although the data have not yet been generated with regard to the usefulness of purging, we believe that this procedure should be undertaken in order to increase the chances of durable remission. In vivo purging studies with high doses of rituximab or with alemtuzumab are ongoing. 34, 35 Both agents are effective against CLL. Their use either alone or in combination may provide a more convenient and possibly a more effective purging strategy. The use of rituximab has been associated in some studies, with late onset neutropenia after autologous SCT for lymphoma. 36 Finally, a major concern arising from high-dose chemotherapy is secondary neoplasms, particularly myelodysplastic syndrome (MDS) and acute leukemia, in these patients with a relatively long natural disease history. Armitage et al 37 reported an incidence of 10% of MDS in 230 patients with lymphoid malignancies treated with high-dose chemotherapy followed by autologous SCT. At the MD Anderson Cancer Center, 22 of 493 patients who received autologous SCT for non-Hodgkin's lymphoma developed AML/MDS. 38 TBI, especially when combined with etoposide, was found to be a significant risk factor in that study.
Allogeneic SCT
There is no evidence that autologous SCT can cure disease, especially in heavily pretreated patients. This has led to the use of allogeneic transplantation. Full allogeneic SCT requires a preparative regimen, which has several purposes. First, it is a dose-intense therapy for hematologic malignancies. These regimens are often limited in dose by the toxic effects to the marrow. The preparative regimen allows for dose intensification with a 'clean' allogeneic marrow rescue given after the therapy. The preparative regimen also ablates immune responses, so that stem cell grafts are not rejected.
Over the last few years, more data have become available with regard to allogeneic transplantation in CLL (Table 3) . 9, 27, 32, [39] [40] [41] [42] [43] Most studies have been small institutional trials and involved a younger patient population. TRM after myeloablative preparative regimens ranged between 10 and 46%.
Owing to advanced age and the indolent nature of the disease, high-dose chemotherapy and allogeneic transplantation was reserved in the earlier trials for patients who failed several regimens and became chemorefractory. In a study from the MD Anderson Cancer Center, 9,40 28 patients with a median age of 43 (range, 26-58 years) were treated. In all, 19 patients had disease that was refractory to fludarabine. The median number of prior chemoregimens was three. The conditioning regimen consisted of high-dose cyclophosphamide 120 mg/kg and fractionated TBI (10.2-12 Gy) in the majority of patients. A total of 20 patients had HLA-identical donors and one had a one-antigenmismatched sibling. Seven patients had a matched unrelated transplant. The median follow-up for the surviving patients was 66 months. Progression-free survival at 5 years was 78% for the chemosensitive patients and 26% for those who were refractory to conventional chemotherapy at the time of transplantation (P ¼ 0.03). Refractoriness was defined as no response or disease progression, while Table 3 Outcome of high-dose chemotherapy and allogeneic SCT for CLL receiving the best conventional therapy available at the time for CLL. Only three patients (10%) died within 100 days of transplant in that study. This was attributed to the lower than expected rate of acute graft-versus-host disease (GVHD); only one patient developed acute grade III GVHD and none had grade IV. This was thought to be related to the pretransplant therapy with fludarabine. 40 The potential impact of fludarabine was retrospectively reassessed in a larger EBMT cohort of 135 patients with CLL who received high-dose chemotherapy and allogeneic transplantation and were reported. 42 In a multivariate Cox model, only prior therapy with fludarabine was found to have an impact on both survival and TRM.
The International Bone Marrow Transplant Registry (IBMTR) recently reported the outcomes of 242 patients with CLL who underwent allogeneic SCT. 43 The median age was 47 years. The eligibility criteria varied, and 16% of patients were in CR at the time of transplantation. OS at 3 years was 45% and the TRM was 40%. Younger patients with lower stage disease had better outcomes.
In the absence of randomized trials, a case-control study was undertaken at the MD Anderson Cancer Center in patients with advanced CLL with progressive disease despite a median of three prior chemotherapy regimens. Allogeneic transplantation had a superior 3-year DFS compared with purged autologous transplants. The rates were 57 and 24%, respectively. 7 Larger comparative studies that have not matched controls were undertaken by the International Project on CLL/Transplant, without showing benefits in survival from allogeneic transplantation. 27 In general, allogeneic transplantation had been reserved for patients with more advanced, refractory disease. In addition, any potential benefit was largely offset by the high rate of transplantrelated mortality, exceeding 40% in the allogeneic group.
Factors relevant to the choice of allogeneic vs autologous SCT

Graft-versus-leukemia
Allogeneic transplantation was originally proposed as a means to escalate the doses of myelotoxic chemotherapy and radiation with bone marrow transplantation to restore hematopoiesis. 44 Considerable evidence indicates that the high-dose preparative regimen does not completely eradicate the CLL in most patients and that an immunemediated GVL effect is important to prevent relapse. Allogeneic transplants in CLL are associated with a lower risk of relapse than syngeneic or purged autologous transplants. 9 Sustained CRs were observed in about 20-30% of patients who were refractory to fludarabine. 9 With conventional chemotherapy alone, those patients would have had a median survival of less than a year.
Further evidence of GVL is observed through the conversion from PCR positivity to PCR negativity spontaneously several months after an allogeneic transplant. 45 Esteve et al reported that in a group of 18 patients who received autografts, minimal residual disease persisted in seven and clinical relapse occurred in six patients after a median follow-up of 15.5 months. In contrast, disease progression was not observed in any of the four patients who had evidence of molecular remission after a median follow-up time of 38 months. 45 The most direct demonstration of the GVL effect is provided by the fact that in patients relapsing after allotransplantation, reinduction of CR may occur after reduction of immunosuppressive therapy, development of GVHD or donor lymphocyte infusion (DLI). 10 Responses to DLI do not appear until several months later and presumably require engraftment and expansion of the relevant effector cells. 46 
Prognostic factors in CLL
Clinical staging systems, introduced almost three decades ago by Rai et al 47 and Binet et al, 48 have been effective in classifying patients with CLL into broad prognostic groups.
Other parameters such as the pattern of marrow involvement, the lymphocyte doubling time, serum levels of beta-2 microglobulin and thymidine kinase also correlate with survival. However, these systems fail to predict accurately the course of the disease in individual patients and do not take into account new discoveries about the molecular pathology of the disease.
Over the last decade, major advancements in our understanding of CLL and its variants have occurred. It has become apparent that there is diversity in types of CLL not only at the clinical level but also at the molecular and cellular levels. The disease can be divided into two subgroups on the basis of the presence or absence of somatic mutations in the specific immunoglobulin heavychain variable-region (IgV H ) genes used by the leukemic cells. The disparity in lifespan is very striking, with a median survival of more than 24 years and 6-8 years for those with or without these mutations, respectively. 14 Chromosomal aberrations are detectable in over 80% of patients with CLL using interphase in situ hybridization. 15 The leukemic cells from patients with no IgV H mutations more frequently have cytogenetic changes that herald poor clinical outcome, such as 11q22-23 deletion, a 17p deletion or p53 dysfunction; whereas the cells from patients with mutated IgV H more frequently have cytogenetic changes associated with a benign clinical course, such as a 13q14 deletion.
The unmutated IgV H is emerging as a crucial adverse prognostic factor in patients with CLL undergoing autologous SCT. In a study by Ritgen et al, 49 time to clinical relapse and time to molecular relapse were significantly shorter in the group with unmutated IgV H . The 2-year probability was 19 vs 0% (P ¼ 0.0008) and 34 vs 9% (P ¼ 0.0006), respectively. This was recently confirmed in another study by Moreno et al, 50 where in a group of 18 patients with CLL undergoing either autologous or allogeneic SCT, the probability of relapse in the groups of patients with unmutated IgV H was 48 and 0% in the groups who received autologous vs allogeneic transplants, respectively (P ¼ 0.02). Although more patients are required to confirm these findings, these preliminary data imply the superiority of allogeneic transplantation in this setting.
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Difficulties in the measurement of IgV H gene mutational status have led, however, to the search for surrogate or equivalent markers.
Expression of CD38, a membrane protein that marks cellular activation and maturation, was found in an initial report to correlate with the IgV H mutational status. 51, 52 However, this finding has varied among subsequent studies. 53 CD38 is now considered as an independent marker of the outcome, with clinical prognostic factor by itself.
With the use of comparative gene-expression profiling, another signaling-associated molecule, the zeta-chainassociated protein 70 (ZAP-70), was recently found to be differentially expressed in the CLL subgroup without IgV H mutations and with poor outcomes. 54 Several published data reported the high correlation between the expression of ZAP-70 and the mutational status of IGVH. [55] [56] [57] Other studies had, however, different findings, 58, 59 suggesting that ZAP-70 expression of CLL B cells has yet to be definitely proven as a surrogate marker for mutational status.
Donor availability
With family sizes shrinking worldwide, the probability of finding HLA-identical donors is decreasing, and increasing the size of the donor pool is much more relevant on a practical basis.
Better techniques for GVHD prophylaxis, including Tcell depletion, will permit the safe use of HLA-mismatched donors, 60 so that the applicability of mismatched allografts will be extended beyond the high-risk patients to which it is confined at the moment.
The growth in the use of cord blood has been limited, thus far, by the small quantities of progenitor cells within individual harvests. 61 The development of sophisticated graft engineering techniques and ex vivo expansion will help to explore the full potential of cord blood transplantation. This will provide a source of allogeneic cells for a number of patients who have no other suitably matched related or unrelated donors available.
Allogeneic SCT with the NMA preparative regimens
Rationale
The potential benefit of high-dose chemoradiotherapy and allogeneic SCT has been offset by the toxicity associated with the conditioning regimen (Table 4 ). Since CLL is generally a disease of older, often debilitated patients, only a minority have been considered eligible for high-dose myeloablative therapies. The high-dose therapy of the preparative regimen is toxic to many tissues, particularly the gastrointestinal tract. High-dose chemoradiotherapy has been shown to increase intestinal permeability. 62 Increased intestinal permeability allows the translocation of bacteria-derived products, such as lipopolysaccharide (LPS), into circulation. LPS plays a critical role in the pathogenesis of GVHD by stimulating host macrophages and other tissues to produce excessive amounts of inflammatory cytokines, most notably tumor necrosis factor-a (TNFa). 63 TNFa affects the integrity of the gut mucosa, and it increases major histocompatibility antigen expression on host tissues, thereby potentiating injury by contributing to the activation of donor cells and increases the incidence of GVHD. Reduced-intensity regimens have been shown to preserve the gut mucosa barrier and decrease the toxicity related to GVHD. 64 
Outcome
Given the potential efficacy of GVL effects in CLL, we evaluated an alternative strategy of utilizing less toxic, NMA preparative regimens with allogeneic hematopoietic transplantation. The goal of the preparative regimen was to achieve sufficient engraftment to prevent graft rejection and to enhance tumor control early after transplantation to allow time for the GVL to become established.
The 'proof of principle' of this strategy was first demonstrated in a phase I trial at MD Anderson Cancer Center. 65 In that feasibility trial, six of nine patients with advanced CLL, which had relapsed or was resistant to fludarabine-based therapy had engraftment with complete chimerism. Four achieved CR. One additional patient with bulky residual lymphadenopathy achieved a CR after a DLI.
A follow-up report has been published recently. 12 In all, 17 patients were studied (Table 5 ). In total, 23% were older than 60 years. The conditioning regimen consisted of 30 mg/m 2 of fludarabine administered intravenously on days -5 to -3 followed sequentially at 4-h intervals by 750 mg/m 2 of cyclophosphamide on the same days. Of the 17 patients, 10 also received rituximab on day À13 (375 mg/ m 2 ) and on days À6, þ 1 and þ 8 (1000 mg/m 2 ). All patients received an allogeneic graft from HLA-matched sibling donor. Prophylaxis for GVHD consisted of a combination of tacrolimus and methotrexate. The 1-year transplant-related mortality rate was 6%.
Current progression-free survival and OS in these patients were compared to rates in a historical group of 20 patients treated at our institution with HDCT and allogeneic transplantation from an HLA-identical sibling. Patients who received HDCT were younger and ranged in age from 26 to 58 years (median, 47 years) (Po0.01). Patients in both groups had comparable survival rates at 2 years: 80% for the NMA group and 60% for the control Stem cell transplantation for CLL E Jabbour et al group of HDCT (P ¼ 0.2). Progression-free survival was also not different between the two groups (44% for the HDCT (95% CI, 22-64%) vs 60% (95%CI, 36-85%) for the NMA group). It should be noted that the day 100 mortality in the group who received HDCT at our institution was 10%, much lower that the rate described in other published studies where it approached 30-40%. The incidence of acute GVHD grade II-IV in the NMA was 29% compared to 51% in the HDCT group. The incidence of chronic GVHD was 58% with HDCT and was not statistically different from that observed in the NMA group.
Potential role of rituxumab in NMA transplantation
Rituximab is an anti-CD20 house-mouse chimeric molecule that significantly increases response rates when used in a combination of fludarabine with or without cyclophosphamide as conventional treatment for CLL. 19 There are several reasons for considering the use of rituximab in the allogeneic transplantation setting. Some reports suggested that it may improve the GVL effect secondary to 'crosspriming' of cytotoxic T cells promoted by apoptosisinduced tumor cell-reactive antibody. 68 Others have reported a lower incidence of GVHD in B-cell-deficient animals, and the rate of GVHD was even lower if the grafts were depleted of B cells. 69 In our study, the NMA preparative regimen was anticipated to provide only transient cytoreduction in these patients with fludarabine-refractory or recurrent disease. Immunomanipulation was performed in patients with persistent or progressive CLL. The general schema of immunomanipulation is depicted in Figure 1 . Rituximab was given at a dose of 375 mg/m 2 Â 1, followed by 1000 mg/ m 2 weekly Â 3 doses. In all, 10 patients with persistent disease underwent immunomanipulation. Seven of these 10 patients had durable complete responses, including three patients who had progressive disease in the presence of GVHD and two who had a partial response. This compares favorably to what has been published in the literature (Table 6 ).
In addition, a significant survival difference was observed in the group of CLL patients who received the combination of fludarabine, cyclophosphamide, and rituximab (FCR) when compared to the patients who received chemotherapy alone (FC) as conditioning regimen. The survival rates were 100 vs 14%, respectively. This difference was attributed to differences in the incidence of chronic GVHD, which was the main cause of death.
Strategies of NMA SCT and their relevance to CLL
CLL is generally a disease of older patients. Therefore, should the goal be to extend the potentially curative approach of NMA to the majority of patients, special attention should be given to the intensity of the preparative regimen used.
As a working definition, a truly NMA regimen should allow autologous recovery of hematopoietic cells within 28 days, without a transplant, and upon engraftment, mixed chimerism should occur. The FCR regimen described has been extensively used in more than 100 patients with B-cell malignancies. OS at 2 years was 80%. The ultimate safety of this procedure has been recently tested in 20 patients with non-Hodgkin's lymphoma who relapsed after a prior treatment with HDCT and autologous transplantation. 70 DFS at 3 years was 95%. Further improvement in the outcome in CLL might occur more in patients who have chemosensitive disease at the time of transplant.
More intense preparative regimens did not translate into an improved outcome, despite the inclusion of younger patients earlier in the course of disease.
The EBMT group reported outcomes in 77 patients who underwent NMA transplantation. 66 A total of 34 (44%) received an intensive conditioning regimen. Transplantrelated mortality was 18% at 12 months. The CR rate was DLI=donor lymphocyte infusion.
Stem cell transplantation for CLL E Jabbour et al 69%, and DFS and the OS at 2 years were 56 and 72%, respectively ( Table 5 ). The Cooperative German Transplant Study Group reported the outcome in 30 patients with CLL undergoing allogeneic SCT after a conditioning regimen consisting of fludarabine, busulfan, and antithymocyte globulin. 67 Among the 30 patients, 15 had a related donor while the others had unrelated donor. Transplant-related mortality was 15%. Acute GVHD grade II-IV was observed in 56%, while chronic GVHD was observed in 75%. Despite more intense chemotherapy, only 40% of patients achieved CR. In addition, none of the six patients who received DLI, with or without chemotherapy, responded.
Therapy for Richter syndrome
CLL in Richter's transformation is associated with a dismal prognosis. When treated with conventional chemotherapy alone, the median survival of these patients was less than 8 months. 71 In a small series of nine patients who received an allogeneic transplantation, three remained alive and in remission at 14, 47 and 67 months, respectively. 72 Two of the three patients in remission received an NMA preparative regimen. The prognosis might be improved by identifying the early signs of transformation; this might include an elevated serum lactate dehydrogenase level or a new positive uptake on gallium-67 scanning. 73 
Future perspectives and conclusions
We are confident that CLL can be transformed from an incurable disease to a curable one. However, this transformation is still in the early phase (Table 7) . Combined chemoimmunotherapy has increased the response rate, but the increase has not translated into a survival benefit yet. Autologous SCT had little effectiveness in patients with advanced disease with multiple relapses. The preliminary results in patients with unmutated IVIg makes the outlook for this strategy even more grim. Autologous SCT needs to be reinvented if it is to play any role at all. Efforts have been focused on achieving minimal residual disease preand post transplantation, perhaps with rituximab and Campath, which are under investigation. A mechanism to simulate a biological activity similar to a GVL effect is needed. Eradication of residual disease may be mediated by immune recognition of these leukemic cells by the host immune system. Trials aiming at ex vivo T-cell expansion are under investigation. 74 Other novel approaches combine autologous SCT with immune-based vaccine strategies. However, the immunodeficiency state of these patients make the potential outlook for these strategies guarded.
Allogeneic SCT remains the only curative approach for CLL, and the advent of nonmyeloablative transplantation may allow larger proportion of patients to benefit from this strategy. Future research will focus further on harnessing GVL without GVHD (Table 7) . NMA transplantation should be the treatment of choice for patients who have failed conventional chemo-antibody treatment. The newly described prognostic factors may allow this strategy to be applied early in the course of the disease, rather than waiting until chemorefractoriness appears. Controlled trials should be encouraged for this purpose. Table 6 Response to immunomodulation post-NMA SCT a. Identification of tumor-associated minor histocompatibility antigens with restricted tissue distribution b. Tumor-specific immunization of the donor prior to allografting c. Inoculation of inactivated malignant cells in the early post transplant period 3. Early identification of patients at high risk of relapse that will permit prophylactic immune manipulation GVL ¼ graft-versus-leukemia; GVHD ¼ graft-versus-host disease; SCT ¼ stem tem cell transplantation.
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